SESSION 1: GASTROINTESTINAL NETs, 2-4:05 p.m. EST
Session Chairs: Ramesh Shivdasani, MD, PhD & Anil Rustgi, MD

1. Rare Cancer Initiative Effort: A Roadmap For Neuroendocrine Tumor Dependency
   Moony (Yuen-Yi) Tseng, Broad Institute (Eli and Edythe L. Broad Institute of MIT and Harvard)

2. Genes that cause multifocal ileal neuroendocrine tumorigenesis and metastasis
   Chris Harris, University of Rochester Medical Center, Wilmot Cancer Institute

3. Whole genome sequencing reveals the independent clonal origin of multifocal ileal neuroendocrine tumors
   Netta Mäkinen, Dana-Farber Cancer Institute

4. Transcriptional and chromatin cascade underlying human enteroendocrine cell differentiation
   Pratik Singh, Dana-Farber Cancer Institute

5. Metabolomic Profile of Gastrointestinal and Pulmonary Neuroendocrine Tumors: Prognostic and Biological Relevance
   Anna La Salvia, Hospital Universitario 12 de Octubre

6. Nanobody-directed CAR T cells eliminate neuroendocrine tumors without toxicity via masking of the antigen target in normal cells
   Xianxin Hua, University of Pennsylvania

Discussion

SPECIAL NETRF PRESENTATION: THE SCIENTISTS BEHIND THE SCIENCE, 4:05-4:15 p.m. EST

SESSION 2: MULTIPLE NETs, 4:15-6:30 p.m. EST
Session Chairs: Lisa Bodei, MD, PhD & George Fisher, PhD

1. Biodistribution and radiation dosimetry of 68Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors
   Simone Krebs, Memorial Sloan Kettering Cancer Center

2. Multimodal analogs of DOTA-JR11 to investigate the unexpected bone marrow toxicity in NET patients
   Susanne Kossatz, Technical University Munich

3. Engineering Decreased Nephrotoxicity for SSTR2 Targeted Alpha Therapy
   David Morse, H. Lee Moffitt Cancer Center & Research Institute

4. uPAR-targeted PRRT: new radionuclide-based therapy
   Andreas Kjaer, Copenhagen University Hospital (Rigshospitalet)

5. Digital Image Analysis in Neuroendocrine Tumors
   Michelle Kim, Icahn School of Medicine at Mount Sinai

6. SV2A PET Imaging for Noninvasive Assessment of Neuroendocrine Differentiation in Neuroendocrine Tumors
   Guiyang Hao, UT Southwestern Medical Center

7. SSTR2-targeted delivery of temozolomide
   Solmaz Aghaamiri, The University of Texas Health Science Center at Houston

Discussion
SESSION 3: PHEO/ PARA & LUNG NETs, 2-4 p.m. EST
Session Chairs: Daniel M. Halperin, MD & Carl M. Gay, MD, PhD

1. Pheochromocytoma organoids as a model to recapitulate cell diversity and function ex vivo
   Patricia Dahia and Alice Soragni, UT Health San Antonio and The Regents of the University of California, Los Angeles

2. Succinate accumulation is not sufficient for tumorigenesis in mouse chromaffin cells but dual loss of SDHB and NF1 yields SDHx-like pheochromocytomas
   Justin Annes, Stanford University

3. Adverse effects of oxygen in a cell culture model for SDHB-mutated Pheochromocytoma/Paraganglioma
   Arthur Tischler, Tufts Medical Center

4. First PET Imaging Studies with 3-[18F]fluoro-p-hydroxyphenethylguanidine ([18F]3F-PHPG) in Paraganglioma and Pheochromocytoma Patients
   David Raffel, The Regents of the University of Michigan

5. Organoid Models of Normal and Malignant Neuroendocrine Cells Reveal Pathways Important for Neuroendocrine Cell Growth, Differentiation, and Transformation
   Talya Dayton, Hubrecht Institute of Developmental Biology and Stem Cell Research

6. Tumor xenografts in zebrafish: a new in vivo model for lung carcinoids
   Giovanni Vitale, Istituto Auxologico Italiano

Discussion

SESSION 4: PANCREAS NETs, 4-6:30 p.m. EST
Session Chairs: James Bibb, PhD & Dawn Quelle, PhD

1. Patient-derived Islet-like Tumoroids reflect phenotypic landscape of original Pancreatic Neuroendocrine Neoplasms and facilitate in vitro drug screening
   Simon L. April-Monn, University of Bern (Universität Bern)

2. RABL6A-Myc signaling promotes pancreatic neuroendocrine tumor cell proliferation and survival
   Ume Salma Shaik Amjad, The University of Iowa

3. Loss of MEN1 function inhibits DNA repair capability of pancreatic neuroendocrine tumors
   Xavier Keutgen, The University of Chicago

4. Loss of Men1 and Pten promotes invasion and metastasis of pancreatic neuroendocrine tumors
   Ziqiang Yuan, Rutgers University Foundation

5. The Importance of DDR genes in Response to PRRT- Evidence for PARP and DNA-PK as Therapeutic Targets to Increase Efficacy
   Rodney Hicks, Peter MacCallum Cancer Centre

6. New pathways for targeting glucose consumption in PNET
   Peter Clark, The Regents of the University of California, Los Angeles

7. Angiopoietin-2/Tie2 signaling regulation of liver metastasis in pancreatic neuroendocrine tumors
   Minah Kim, Columbia University Medical Center

8. The role of the B7x signaling pathway in the development and progression of neuroendocrine tumors
   Steven Libutti, Rutgers, The State University of New Jersey

Discussion

End of Meeting, Elyse Gellerman